{"id":390827,"date":"2017-11-30T00:00:00","date_gmt":"2017-11-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0014-biopharma-chronic-heart-failure-treatment-algorithms-claims-data-analysis-us-2017-november\/"},"modified":"2026-03-31T10:49:26","modified_gmt":"2026-03-31T10:49:26","slug":"algocv0014-biopharma-chronic-heart-failure-treatment-algorithms-claims-data-analysis-us-2017-november","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0014-biopharma-chronic-heart-failure-treatment-algorithms-claims-data-analysis-us-2017-november\/","title":{"rendered":"Chronic Heart Failure | Treatment Algorithms | Claims Data Analysis | US | 2017 November"},"content":{"rendered":"<p>First-line treatment of chronic heart failure (<abbr title=\"chronic heart failure\">CHF<\/abbr>) usually involves a\u00a0beta blocker, an angiotensin-converting enzyme (<abbr title=\"angiotensin-converting enzyme\">ACE<\/abbr>) inhibitor, and\u00a0 an oral diuretic. Second- or third-line treatments are\u00a0often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which consist of\u00a0drug options. The <abbr title=\"chronic heart failure\">CHF<\/abbr> market is heavily genericized, as such physician practice is minimally impacted\u00a0by pricing pressures. The <abbr title=\"chronic heart failure\">CHF<\/abbr> Treatment Algorithm offers insight into prescribing patterns in this multi-layered treatment landscape where\u00a0few branded agents jostle for patient share in a crowded sector.\u00a0 That said, small patient shares for such a prevalent indication can translate into significant commercial positions.<\/p>\n","protected":false},"template":"","class_list":["post-390827","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390827\/revisions"}],"predecessor-version":[{"id":393951,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390827\/revisions\/393951"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}